NEW YORK — Irish diagnostics firm Trinity Biotech said on Monday that it has signed an agreement to provide laboratory testing services for Imaware as part of a broader digital health alliance.
As part of the alliance, Trinity will make a $1.5 million convertible note investment in Austin, Texas-based Imaware.
Under the terms of the five-year deal, Trinity will process Imaware's test kits — which include ones for celiac disease, testosterone level monitoring, and diabetes screening — at its New York-based reference lab, with the goal of processing over 650,000 tests annually by the third year of the agreement.
The companies said that they will focus on providing the tests for private and white label use by digital health channel customers.
"Our partnership with Trinity Biotech will significantly expand our … ability to meet the testing needs of our B2B clients, who are delivering virtual care protocols to millions of patients," Imaware Cofounder Jani Tuomi said in a statement. "Additionally, we plan to integrate the complete suite of Trinity Biotech testing methodologies, covering point-of-care, rapid self-test, and lab-based tests, into the Imaware digital platform."